

Substitute for form 1449/PTO (Revised 07/2007) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/577,642	
				Filing Date		November 20, 2006	
				First Named Inventor		Long	
				Art Unit		1644	
				Examiner Name		Gambel, Phillip	
Sheet	1	of	2	Attorney Docket Number		035784/311261	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	12	US-5,397,703	03-14-1995	de Boer <i>et al.</i>	
	13	US-5,677,165	10-14-1997	de Boer <i>et al.</i>	
	14	US-5,874,082	02-23-1999	de Boer	
	15	US-6,004,552	12-21-1999	de Boer <i>et al.</i>	
	16	US-6,056,959	05-02-2000	de Boer <i>et al.</i>	
	17	US-6,315,998 B1	11-13-2001	de Boer <i>et al.</i>	
	18	US-6,899,879 B2	05-31-2005	de Boer <i>et al.</i>	
	19	US-20070098717 A1	05-03-2007	Long <i>et al.</i>	
	20	US-20070098718 A1	05-03-2007	Long <i>et al.</i>	
	21	US-20070218060 A1	09-20-2007	Long <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	22	WO 94/01547 A3	01-20-1994	Cetus Oncology Corporation		
	23	WO 95/17202 A1	06-29-1995	Immunex Corporation		
	24	WO 96/18413 A1	06-20-1996	The University of Birmingham		
	25	WO 97/31025 A1	08-28-1997	Chiron Corporation		
	26	WO 99/42075 A2	08-26-1999	Bristol-Myers Squibb Company		
	27	WO 02/028481 A2	04-11-2002	Chiron Corporation		
	28	WO 02/060485 A2	08-08-2002	IDEC Pharmaceuticals Corporation		
	29	WO 2005/044294 A2	05-19-2005	Chiron Corporation		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2007) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/577,642	
				Filing Date		November 20, 2006	
				First Named Inventor		Long	
				Art Unit		1644	
				Examiner Name		Gambel, Phillip	
Sheet	2	of	2	Attorney Docket Number		035784/311261	

FOREIGN PATENT DOCUMENTS						
	30	WO 2005/044305 A2	05-19-2005	Chiron Corporation		
	31	WO 2005/044306 A2	05-19-2005	Chiron Corporation		
	32	WO 2005/044307 A2	05-19-2005	Chiron Corporation		
	33	WO 2005/044854 A2	05-19-2005	Chiron Corporation		
	34	WO 2005/044855 A2	05-19-2005	Chiron Corporation		

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	35	BALINT, R., <i>et al.</i> , "Antibody Engineering by Parsimonious Mutagenesis," <i>Gene</i> , 1993, pp. 109-118, Vol. 137, No. 27.	
	36	HAGER A-C MALMBORG, <i>et al.</i> , "Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies," <i>Scandinavian Journal of Immunology</i> , 2003, pp. 517-524, Vol. 57, No. 6.	
	37	LITTLE, M., <i>et al.</i> , "Of Mice and Men: Hybridoma and Recombinant Antibodies," <i>Review Immunology Today</i> , 2000, pp. 364-370, Vol. 21.	
	38	TAI, Y., <i>et al.</i> , "Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications," <i>Cancer Research</i> , 2004, pp. 2846-2852, Vol. 64, No. 8.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.